Tesla’s latest Cybertruck recall looks ugly at first glance, but investors remain far more focused on the company’s expanding AI and autonomy potential.
Brainsway (NASDAQ:BWAY) reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recurring revenue base.
Chief Executive Officer Hadar Levy said on the company’s earnings call that rev
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved.
On the company’s first-quar
Applied Optoelectronics (NASDAQ:AAOI) expects a sharp second-half ramp in its data center optics business as demand for higher-speed transceivers continues to outstrip the company’s manufacturing capacity, Chief Strategy Officer and Chief Financial Officer Dr. Stefan Murry said at Needham’s 21st Ann
Bilfinger (ETR:GBF) confirmed its 2026 outlook after reporting a slower start to the year, with management pointing to severe winter weather and geopolitical uncertainty as factors that delayed customer decisions and pressured operations in the first quarter.
Group CEO Thomas Schulz said orders rec
Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter.
Group Chief Executive Officer Kai
Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company’s earnings call.
Chi
Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the second half of 2026, as the company reported first-quarter financial results and provided updates acr
Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioengineered vascular products.
On the company’s earnings call, President and Chief Executive Officer
Brenntag (ETR:BNR) said its first-quarter 2026 results reflected a slow start to the year followed by a sharp improvement in March as volatility tied to the crisis in the Middle East lifted pricing and prompted some customers to rebuild inventories.
On the company’s earnings call, Chief Operating O
Deutsche Telekom (ETR:DTE) reported what Chief Executive Tim Höttges called a “robust” start to 2026, citing broad-based growth across the group and an upgraded full-year outlook following stronger guidance from T-Mobile US.
On the company’s first-quarter earnings call, Höttges said group organic s
MLP (ETR:MLP) reported record first-quarter revenue and earnings for 2026, with Chief Financial Officer Reinhard Loose saying the financial services group remained on its medium-term growth path despite market volatility and macroeconomic uncertainty.
On the company’s earnings call, Loose said tota
RWE Aktiengesellschaft (ETR:RWE) reported a stronger first quarter for fiscal 2026, with Chief Financial Officer Michael Müller telling analysts that the company had a “good start” to the year and was increasingly confident in meeting its full-year targets.
Müller said adjusted EBITDA rose 25% year
Atour Lifestyle (NASDAQ:ATAT) reported sharply higher first-quarter revenue for 2026, driven by continued expansion of its hotel network and strong growth in its retail business, while management said China’s hotel market is continuing a “moderate recovery” with a shift toward quality and differenti
